Precision Aq - International

Precision Aq - International company information, Employees & Contact Information

Precision AQ helps life science companies navigate the complexities of commercialisation across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life changing medicines. Welcome to the Precision AQ LinkedIn page showcasing the talents of our International team, operating within the global Precision network of 4,000+ specialists spanning over 100 disciplines. Please also follow us on our Global Precision AQ LinkedIn page. Our international teams are headquartered in London, UK, and have offices across Europe. The international team includes the recent acquisition businesses of Across Health and Makara Health. Our International matrix structure fosters deep collaboration across geographies and specialisms, enabling us to deliver tailored strategies that meet the specific needs of local markets while maximising global impact. 𝗢𝘂𝗿 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴𝘀 𝘀𝗽𝗮𝗻: • Access Strategy: Health Economics & Outcomes Research (HEOR), Pricing & Market Access (P&MA) • Omnichannel Solutions: Navigator365 Data & Insights, Strategic Consulting, Campaign Analytics, Learning & Development • Healthcare Communications: Medical Education, Brand Promotion, Learning & Development, Patient Insights & Support, and PR We partner with pharmaceutical and life science organisations to co-create impactful, data-driven programmes that unlock access to medicines, elevate customer engagement, and support patient outcomes. Our shared goal is to deliver value in every interaction we have with our clients – thanks to our combination of highly experienced strategic experts, proprietary data and award-winning creative teams. Whether shaping a communications or medical strategy, designing an omnichannel roadmap, or driving access to life changing medicines for patients, we combine real-world evidence, creative excellence, and strategic insight to deliver meaningful healthcare impact across the product lifecycle.

Company Details

Employees
123
Address
29 Throgmorton Street, Ec2n 2at, London,united Kingdom
Industry
Business Consulting And Services
NAICS
Management, Scientific, and Technical Consulting Services
Management Consulting Services
Other Scientific and Technical Consulting Services
Other Management Consulting Services
HQ
London
Looking for a particular Precision Aq - International employee's phone or email?

Precision Aq - International Questions

News

From insight to impact: strengthening stakeholder engagement across the patient journey - PMLiVE

From insight to impact: strengthening stakeholder engagement across the patient journey PMLiVE

Precision AQ: 2025 - PharmaLive

Precision AQ: 2025 PharmaLive

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - GlobeNewswire

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference GlobeNewswire

Precision AQ Expands Powerhouse Access Experience Team (AET) to Tackle Evolving Patient Access Challenges in Rare Disease - PR Newswire

Precision AQ Expands Powerhouse Access Experience Team (AET) to Tackle Evolving Patient Access Challenges in Rare Disease PR Newswire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire

EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals

EyePoint Announces Participation at Upcoming Investor Conferences EyePoint Pharmaceuticals

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Sahm

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference Sahm

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - FinancialContent

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting FinancialContent

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EyePoint Pharmaceuticals

Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478 - Yahoo Finance

Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478 Yahoo Finance

Precision AQ Launches Navigator365™ Matrix, an Advanced Platform for Identifying Digital Opinion Leaders to Activate and Amplify Brand Messages - PR Newswire

Precision AQ Launches Navigator365™ Matrix, an Advanced Platform for Identifying Digital Opinion Leaders to Activate and Amplify Brand Messages PR Newswire

Disc Medicine to Participate in Upcoming Investor Conferences | User | poteaudailynews.com - FinancialContent

Disc Medicine to Participate in Upcoming Investor Conferences | User | poteaudailynews.com FinancialContent

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities - Business Wire

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities Business Wire

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference - EyePoint Pharmaceuticals

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference EyePoint Pharmaceuticals

Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development - Yahoo Finance

Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development Yahoo Finance

MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner - Business Wire

MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner Business Wire

Precision Value & Health Unveils New Identity: Precision AQ - PR Newswire

Precision Value & Health Unveils New Identity: Precision AQ PR Newswire

EyePoint to Present at Guggenheim SMID Cap Biotech Conference - EyePoint Pharmaceuticals

EyePoint to Present at Guggenheim SMID Cap Biotech Conference EyePoint Pharmaceuticals

Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 EyePoint Pharmaceuticals

Precision Value and Health Unveils New Identity: Precision AQ - PharmiWeb.com

Precision Value and Health Unveils New Identity: Precision AQ PharmiWeb.com

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference GlobeNewswire

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) - Yahoo Finance

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) Yahoo Finance

Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases - Business Wire

Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases Business Wire

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update - Business Wire

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update Business Wire

EyePoint Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Quiver Quantitative

EyePoint Pharmaceuticals Announces Participation in Upcoming Investor Conferences Quiver Quantitative

Seismic Therapeutic Appoints Sophie Jones, M.D., as Chief Financial Officer - Business Wire

Seismic Therapeutic Appoints Sophie Jones, M.D., as Chief Financial Officer Business Wire

City Therapeutics Expands Executive Team and Board of Directors - Business Wire

City Therapeutics Expands Executive Team and Board of Directors Business Wire

DE&I in clinical trials: the role of health literacy and AI - PMLiVE

DE&I in clinical trials: the role of health literacy and AI PMLiVE

City Therapeutics Appoints Andy Orth as Chief Executive Officer - Business Wire

City Therapeutics Appoints Andy Orth as Chief Executive Officer Business Wire

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors - Business Wire

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors Business Wire

Contact the Board - EyePoint Pharmaceuticals

Contact the Board EyePoint Pharmaceuticals

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy - Business Wire

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy Business Wire

MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner - Business Wire

MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner Business Wire

MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, as Entrepreneur Partner - Business Wire

MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, as Entrepreneur Partner Business Wire

Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline - Business Wire

Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline Business Wire

Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC) - Business Wire

Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC) Business Wire

New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction - FinancialContent

New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction FinancialContent

Top Precision Aq - International Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant